SAGE Therapeutics (SAGE) Defended at Raymond James, Says Selloff is Overreaction

Ionis Pharma (IONS) Highlights Top-Line Data from Phase 1/2 Study of ONIS-HTTRx (RG6042) at AAN Meetings

April 24, 2018 12:17 PM EDT

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today presented top-line data from the Phase 1/2 study of IONIS-HTTRx (RG6042) in people with early stage Huntington's disease (HD) at the 70th American Academy of Neurology (AAN) meeting in Los Angeles, California. Results from exploratory analyses of data from the study demonstrated correlations between reductions in mutant huntingtin (mHTT), the disease-causing protein, and improvements in clinical measures of Huntington's disease.

HD is a rare, progressive,... More

Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q

April 24, 2018 8:48 AM EDT

Piper Jaffray reiterated an Overweight rating and $407.00 price target on Biogen (NASDAQ: BIIB) following the company's 1Q earnings report. BIIB posted total revenue of $3,131M, missing consensus $3,152M but beating Piper Jaffray's $3,080M estimate. Non-GAAP EPS of $6.05 easily beat consensus $5.93.

BIIB's anti-CD20... More

Biogen (BIIB) Tops Q1 EPS by 13c, Miss on Revenues

April 24, 2018 7:00 AM EDT

Biogen (NASDAQ: BIIB) reported Q1 EPS of $6.05, $0.13 better than the analyst estimate of $5.92. Revenue for the quarter came in at $3.1 billion versus the consensus estimate of $3.15 billion.

Total revenues of $3.1 billion, an 11% increase versus the prior year or a 15% increase excluding hemophilia... More

Sage Therapeutics (SAGE) Weakness is a Buying Opportunity - RBC

April 23, 2018 10:20 AM EDT

RBC Capital analyst Brian Abrahams sees weakness in Sage Therapeutics (NASDAQ: SAGE) on Friday, related to insider selling and a deal with Biogen for IONS, as a buying opportunity.

"... we view these as non-fundamental, and Friday's detailed, in-line brexanolone data, today's on-track NDA filing,... More

Nomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS Collaboration

April 23, 2018 8:14 AM EDT

Nomura/Instinet reiterated a Buy rating and $420.00 price target on Biogen (NASDAQ: BIIB) following the company's announced details of an expanded collaboration with IONS to develop CNS-delivered antisense oligonucleotides. The deal was not considered in BIIBs prior financial guidance.

The IONS... More

Biogen (BIIB) Reports New SPINRAZA (nusinersen) Data at AAN Meetings

April 23, 2018 7:33 AM EDT

Biogen (NASDAQ: BIIB) today announced new findings detailing the benefits that SPINRAZA® (nusinersen) demonstrates for both infantile- and later-onset spinal muscular atrophy (SMA) populations, including improvement in motor function as well as increased survival for the most severely affected. These findings are based on interim results from the SHINE open-label extension study and an analysis of SPINRAZAs... More